Literature DB >> 3263890

The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects.

H K Nielsen1, K Thomsen, E F Eriksen, P Charles, T Storm, L Mosekilde.   

Abstract

The effects of 40 mg of prednisone given daily for 5 days to normal individuals on serum levels of bone Gla-protein (BGP), alkaline phosphatase, calcium phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone (S-iPTH) and on renal excretions of calcium, phosphate and hydroxyproline were evaluated in a double-blind, placebo controlled study. In the prednisone group a 75% decrease (P less than 0.001) was found in serum BGP compared to a 6% decrease (P less than 0.05) in serum alkaline phosphatase. The renal hydroxyproline excretion remained unchanged. Serum calcium was unchanged while the fasting urinary calcium excretion showed a 2-fold increase (P less than 0.001). Serum 1,25-dihydroxyvitamin D increased (P less than 0.01) in spite of unchanged serum 25-hydroxyvitamin D, serum phosphate and parathyroid function (as judged by S-iPTH and the maximal tubular reabsorption capacity for phosphate (TmP/GFR]. The data suggest a direct inhibition of osteoblast number and/or function by short-term glucocorticoid administration with unchanged bone resorption leading to a negative bone mineral balance. The increase in serum 1,25-dihydroxyvitamin D is probably due to a direct stimulation by glucocorticoids of the renal 1 alpha-hydroxylase. The effects of the vitamin D metabolite, however seem to be blunted.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263890

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  9 in total

1.  Effect of different doses of nasal salmon calcitonin on bone mass.

Authors:  G Thamsborg; T L Storm; R Sykulski; E Brinch; H K Nielsen; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1991-05       Impact factor: 4.333

2.  Steroid-induced hypocalcaemia with tetany in a patient with hypoparathyroidism.

Authors:  Dimitrios Oikonomou; Ageliki Laina; Aikaterini Xydaki; Constantinos Christopoulos
Journal:  BMJ Case Rep       Date:  2014-11-18

3.  Effect of raloxifene in human neurocysticercosis.

Authors:  Alan Scott Sacerdote; Javier O Mejía; Gül Bahtiyar; Oskar Salamon
Journal:  BMJ Case Rep       Date:  2012-06-14

Review 4.  Corticosteroid-Induced osteoporosis: detection and management.

Authors:  J D Adachi; A Papaioannou
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Effect of low-dose methylprednisolone on calcium balance and bone composition in rats.

Authors:  A Voulgaris; C Liapi; J Papadopoulos
Journal:  J Endocrinol Invest       Date:  1997-12       Impact factor: 4.256

6.  Serum bone Gla protein and carboxyterminal cross-linked telopeptide of type I collagen in patients with Cushing's syndrome.

Authors:  A Sartorio; A Conti; S Ferrario; E Passini; T Re; B Ambrosi
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

7.  Bone turnover during short course prednisolone treatment in patients with chronic obstructive airways disease.

Authors:  D Morrison; N J Ali; P A Routledge; S Capewell
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

8.  A large volume spacer significantly reduces the effect of inhaled steroids on bone formation.

Authors:  K Meeran; J M Burrin; K A Noonan; C P Price; P W Ind
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

Review 9.  Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update.

Authors:  Emily S Mohn; Hua J Kern; Edward Saltzman; Susan H Mitmesser; Diane L McKay
Journal:  Pharmaceutics       Date:  2018-03-20       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.